As trials progress, updates are often made. Please find below information on the latest updates to the STATIC trial:
“We are working on an update to allow people with CLL who have been treated with acalabrutinib as their second or subsequent line of treatment to join the trial. They will then be randomly selected to have either continuous treatment with acalabrutinib or pause their treatment until their CLL comes back, the same as people on the trial on ibrutinib.
As part of this update people with CLL who have been treated with ibrutinib as their first and only of treatment as part of the IcICLLe trial or in standard care within the NHS will also be able to join the trial. They will then be randomly selected to have either continuous treatment with ibrutinib or pause their treatment until their CLL comes back.
Not all hospitals that are on the STATIC trial will make these changes at the same time, therefore, please ask your hospital team directly about joining the trial.”
Find out more about STATIC here.
For those unfamiliar with the trial, it aims “to find out whether people with Chronic Lymphocytic Leukaemia (CLL) who have had a good response to ibrutinib or acalabrutinib can take a break from treatment and only restart treatment if the CLL comes back”.
It compares “whether having a break from treatment with ibrutinib or acalabrutinib will work as well as continuing treatment without a break.”
As well, it will test “whether taking a break from treatment reduces side effects, whether it lowers the risk of CLL becoming resistant to ibrutinib or acalabrutinib, and whether there is any difference in the overall cost of CLL treatment.”
STATIC research also wants to know “whether having a break from ibrutinib or acalabrutinib changes how participants are feeling emotionally, and what they like and do not like about having treatment which includes breaks”.
26 November 2024